Log in

OTCMKTS:UCBJFUCB Stock Price, Forecast & News

+1.50 (+1.30 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $117.20
50-Day Range
MA: $101.95
52-Week Range
Now: $117.20
Volume301 shs
Average Volume727 shs
Market Capitalization$22.80 billion
P/E Ratio20.14
Dividend YieldN/A
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Read More
UCB logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$5.50 billion
Cash Flow$5.68 per share
Book Value$40.36 per share



Market Cap$22.80 billion
Next Earnings Date7/27/2020 (Confirmed)
OptionableNot Optionable

Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter.

UCB (OTCMKTS:UCBJF) Frequently Asked Questions

How has UCB's stock been impacted by COVID-19 (Coronavirus)?

UCB's stock was trading at $97.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UCBJF stock has increased by 20.6% and is now trading at $117.20. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of UCB?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for UCB.

When is UCB's next earnings date?

UCB is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for UCB.

Has UCB been receiving favorable news coverage?

Media headlines about UCBJF stock have trended negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. UCB earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future. View the latest news about UCB.

Who are some of UCB's key competitors?

Who are UCB's key executives?

UCB's management team includes the following people:
  • Jean-Christophe Tellier, Chief Executive Officer & Executive Director
  • Charl van Zyl, Chief Operating Officer
  • Detlef Thielgen, Chief Financial Officer & Executive Vice President
  • Iris Löw-Friedrich, Chief Medical Officer & Executive Vice President
  • Dhavalkumar Patel, Chief Scientific Officer & EVP

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $117.20.

How big of a company is UCB?

UCB has a market capitalization of $22.80 billion and generates $5.50 billion in revenue each year. The company earns $887.04 million in net income (profit) each year or $5.82 on an earnings per share basis. UCB employs 7,606 workers across the globe.

What is UCB's official website?

The official website for UCB is www.ucb.com.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.